Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Lucía Pérez-Lamas, Juan Carlos Hernandez Boluda, Luis Felipe Casado Montero, Maria Teresa Gómez Casares, Rosa Ayala, Blanca Xicoy, Francisca Ferrer Marin, Guillermo Orti, Raquel De Paz Arias, Santiago Osorio Prendes, Raul Perez Lopez, Elvira Mora, Concepción Ruiz Nuño, Antonio Jimenez Velasco, Concepcion Boque, Magdalena Sierra Pacho, Joaquin Martinez Lopez, Valentin Garcia Gutierrez

Blood (2023) 142 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2023-184989

Published: 2023

Journal Articles

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Blood (2023) 142 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2023-177715

Published: 2023

Journal Articles

Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Blood (2022) 140 (Supplement 1): 7754–7756.

https://doi.org/10.1182/blood-2022-164561

Published: 2022

Journal Articles

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Blood (2022) 140 (Supplement 1): 7631–7633.

https://doi.org/10.1182/blood-2022-167747

Published: 2022

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Blood (2022) 140 (Supplement 1): 665–667.

https://doi.org/10.1182/blood-2022-160000

Published: 2022

Journal Articles

Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors

Blood (2022) 140 (Supplement 1): 6730–6732.

https://doi.org/10.1182/blood-2022-163070

Published: 2022

Journal Articles

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

Blood (2021) 138 (Supplement 1): 3954.

https://doi.org/10.1182/blood-2021-147684

Published: 2021

Journal Articles

A Phase 1b/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, TP53 WT , Ph+ Chronic Myeloid Leukemia

Jorge E. Cortes, Omer Hassan Jamy, Guillermo Ortí, Felipe Prosper, Sebastian Grosicki, Anne Uyei, Wayne P. Rothbaum, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 2562.

https://doi.org/10.1182/blood-2021-145218

Published: 2021

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

A High Dose of Naïve CD8 + T-Cells Increases the Incidence of Graft-Versus-Host Disease (GvHD) after Donor Lymphocyte Infusions (DLIs) from HLA Identical Sibling Donors

Guillermo Ortí, Carlos Palacio, Irene García-Cadenas, Isabel Sánchez-Ortega, María-José Jimenez, MD, Carmen Azqueta, Guillermo Villacampa, Christelle M Ferra, Rocio Parody, Rodrigo Martino, Francesc Bosch, MD PhD, David Valcarcel, Sergio Querol

Blood (2019) 134 (Supplement_1): 3292.

https://doi.org/10.1182/blood-2019-124358

Published: 2019

Journal Articles

Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab

Juan C Nieto, PhD, Elisa Roldan, MD, Isabel Jiménez, MSc, Laura Fox, Júlia Carabia, PhD, Guillermo Orti, Lluis Puigdefàbregas, Laura Gallur, Gloria Iacoboni, MD, Priyanka Raheja, Ana Perez, Olga Salamero, MD, Carlos Palacio, David Valcarcel, MD, Marta Crespo, PhD, Francesc Bosch, MD, Pere Barba, MD

Blood (2018) 132 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2018-99-114887

Published: 2018

Journal Articles

Ruxolitinib in Refractory Acute and Chronic Graft-Versus-Host Disease: A Multi-Center Survey Study

Blood (2017) 130 (Supplement 1): 1983.

https://doi.org/10.1182/blood.V130.Suppl_1.1983.1983

Published: 2017

Journal Articles

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Blood (2017) 130 (Supplement 1): 1624.

https://doi.org/10.1182/blood.V130.Suppl_1.1624.1624

Published: 2017

Journal Articles

Donor Lymphocyte Infusions for Haematological Malignancy Relapse

Guillermo Orti, MD, Irene García-Cadenas, MD, Isabel Sánchez-Ortega, MD PhD, Mª Jose Jimenez, MD, Laura Alonso, MD, Carmen Azqueta, PhD, Cristina Diaz de Heredia, MD, Cristelle Ferra, MD, Rocio Parody, MD PhD, Jorge Sierra, MD PhD, Sergio Querol, MD PhD, David Valcarcel, MD PhD

Blood (2016) 128 (22): 5775.

https://doi.org/10.1182/blood.V128.22.5775.5775

Published: 2016

Journal Articles

An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

Mohamed A. Kharfan-Dabaja, MD, Rocio Parody, MD, Janelle Perkins, PharmD, Oriana Lopez-Godino, MD, Lucia Lopez-Corral, MD, Lourdes Vazquez, MD, Dolores Caballero, MD, Jose Falantes, MD, Jamie Shapiro, PharmD, Guillermo Orti, MD, Pere Barba, MD, David Valcárcel, MD PhD, Alber Esquirol, MD, Rodrigo Martino, MD PhD, Jose Luis Piñana, MD, Carlos Solano, MD, Joseph A Pidala, MD, PhD, Claudio Anasetti, MD, Jose A. Perez-Simon, MD, PhD

Blood (2015) 126 (23): 3142.

https://doi.org/10.1182/blood.V126.23.3142.3142

Published: 2015

Journal Articles

Extracorporeal Photopheresis As Second Line Therapy for Steroid Refractory Acute Gvhd: Retrospective Study of Long-Term Outcomes

Rohini Radia, MBChB, Emma Das-Gupta, MD, Guillermo Orti, MD, Donal McLornan, MDPhD, Majid A. Kazmi, Christopher P Fox, PhD, Jenny L. Byrne, PhD, Nigel H. Russell, MD, Kavita Raj, MDPhD

Blood (2015) 126 (23): 1944.

https://doi.org/10.1182/blood.V126.23.1944.1944

Published: 2015

Journal Articles

Outcome of Second Allogeneic SCT Following Relapse of Hematological Malignancies After a First Allogeneic SCT

Blood (2011) 118 (21): 3056.

https://doi.org/10.1182/blood.V118.21.3056.3056

Published: 2011

Journal Articles

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Blood (2010) 116 (16): 3080–3088.

https://doi.org/10.1182/blood-2010-05-286856

Published: 2010

Journal Articles

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning

Adam J. Mead, Kirsty J. Thomson, Emma C. Morris, Sajir Mohamedbhai, Shari Denovan, Guillermo Orti, Adele K. Fielding, Panagiotis D. Kottaridis, Rachael Hough, Ronjon Chakraverty, David C. Linch, Stephen Mackinnon, Karl S. Peggs

Blood (2010) 115 (25): 5147–5153.

https://doi.org/10.1182/blood-2010-01-265413

Published: 2010

Includes: Supplemental data

NARROW

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

A Phase 1b/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, TP53 WT , Ph+ Chronic Myeloid Leukemia

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

A High Dose of Naïve CD8 + T-Cells Increases the Incidence of Graft-Versus-Host Disease (GvHD) after Donor Lymphocyte Infusions (DLIs) from HLA Identical Sibling Donors

Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab

Ruxolitinib in Refractory Acute and Chronic Graft-Versus-Host Disease: A Multi-Center Survey Study

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Donor Lymphocyte Infusions for Haematological Malignancy Relapse

An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

Extracorporeal Photopheresis As Second Line Therapy for Steroid Refractory Acute Gvhd: Retrospective Study of Long-Term Outcomes

Outcome of Second Allogeneic SCT Following Relapse of Hematological Malignancies After a First Allogeneic SCT

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only